Home
Clinical Trials
Compassionate Use of Tetraben...

Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements

NCT ID: NCT00642057

Last Updated: 2023-03-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

NCT05206513

Dyskinesia Cerebral Palsy

ACTIVE_NOT_RECRUITING PHASE3

Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease

NCT04478734

Huntington Disease

RECRUITING PHASE2

Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

NCT00135993

Restless Legs Syndrome

COMPLETED PHASE3

Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia

NCT00950196

Ataxia Chorea Dystonia +2 more

COMPLETED PHASE4

Coenzyme Q10 in Adult-Onset Ataxia

NCT00957216

Sporadic Ataxia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the protocol is to provide compassionate use of an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperkinetic Movement Disorders

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tetrabenazine

25 mg titrated to optimal dose per patient

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects evaluated here at Baylor in the PDCMDC demonstrating need for tetrabenazine treatment.
* Willing to sign informed consent.
* Willing to comply with procedures required as part of this study.